EGFR degradation or inactivation represents a novel approach for NASH–HCC treatment and prevention, and the GR–MIG6 axis is a newly defined target that can be activated by HNK and related compounds. This evidence concerns the gene NR3C1 and metabolic dysfunction-associated steatohepatitis.